Axsome Q3 revenue $104.8M (+81% YoY); Auvelity $80.4M (+113%); net loss $64.6M

Axsome Therapeutics, Inc.

2024-Q3 EPS reported -$4.45 revenue$266,927,000

Total net product revenue $104.8M, up 81% YoY; Auvelity $80.4M (+113%), Sunosi $24.4M (+21%).
Net loss $64.6M ($1.34 loss per share); cash and equivalents $327.3M at Sept 30, 2024.
Auvelity sales force to expand to ~300 reps in Q1 2025 due to strong demand growth.
AXS-07 migraine NDA resubmission accepted with PDUFA goal date January 31, 2025.
Topline results for AXS-05 (AD agitation) and AXS-12 (narcolepsy) on track for Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.